(2R,3R)-2-[(1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)morpholine is a chiral morpholine derivative. It is a key synthetic intermediate in the production of aprepitant, a neurokinin-1 (NK1) receptor antagonist. Aprepitant is an active pharmaceutical ingredient (API) used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). This compound is a critical building block that introduces the chiral, sterically hindered aryl ether moiety essential for the high-affinity binding of aprepitant to the NK1 receptor. Its synthesis and isolation in high enantiomeric purity are crucial steps in the manufacturing process of the final drug substance. The presence of the trifluoromethyl groups and the fluorophenyl ring are structural features that contribute to the overall pharmacokinetic and pharmacodynamic profile of the resulting API. As a sophisticated chiral intermediate, it is not a commodity chemical but a specialized product used exclusively in pharmaceutical synthesis. Its handling requires standard laboratory safety precautions for organic compounds.